<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02486406</url>
  </required_header>
  <id_info>
    <org_study_id>M14-748</org_study_id>
    <secondary_id>2015-000111-41</secondary_id>
    <nct_id>NCT02486406</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects</brief_title>
  <acronym>ZIRCON</acronym>
  <official_title>An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this three part study is to evaluate the pharmacokinetics (Part 1),
      safety/efficacy (Part 2), and long-term follow-up (Part 3) of ombitasvir (OBV), paritaprevir
      (PTV), ritonavir (RTV) with or without dasabuvir (DSV) and with or without ribavirin (RBV) in
      pediatric subjects with genotype 1 or 4 chronic hepatitis C virus (HCV) infection.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 28, 2015</start_date>
  <completion_date type="Anticipated">November 26, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 9, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part1: Maximum plasma concentration (Cmax) of OBV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Maximum plasma concentration (Cmax) of PTV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Lowest plasma concentration (Ctrough) of OBV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: concentration of drug in blood plasma against time [Area under the curve (AUC)] of OBV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: concentration of drug in blood plasma against time [Area under the curve (AUC)] of RTV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: concentration of drug in blood plasma against time [Area under the curve (AUC)] of PTV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Maximum plasma concentration (Cmax) of DSV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Lowest plasma concentration (Ctrough) of DSV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: concentration of drug in blood plasma against time [Area under the curve (AUC)] of DSV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Percentage of participants who relapse out of participants who achieved sustained virologic response (SVR) in Part 1 or Part 2 of the study.</measure>
    <time_frame>Any time up to the last follow-up in this study, approximately 4 years.</time_frame>
    <description>Relapse is defined as confirmed HCV RNA ≥ LLOQ for a subject with HCV RNA &lt; LLOQ at Final Treatment Visit who completes treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Maximum plasma concentration (Cmax) of RTV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Lowest plasma concentration (Ctrough) of PTV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Lowest plasma concentration (Ctrough) of RTV</measure>
    <time_frame>Pharmacokinetic (PK) samples will be collected at the following timepoints: • Day 1: 4 hours postdose • Week 2: 2, 4, 8, 12 and 24 hours postdose • Week 4: a PK sample • Week 8: a trough PK sample • Week 12: a PK sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Percentage of participants with sustained virologic response 12 weeks after the last actual dose of study drug (SVR12).</measure>
    <time_frame>Either 24 weeks or 36 weeks after starting study drug depending on treatment duration (12 or 24 weeks of treatment respectively).</time_frame>
    <description>HCV RNA &lt; Lower limit of quantification (LLOQ) 12 weeks after the last actual dose of study drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Percentage of participants who have new HCV infection</measure>
    <time_frame>Any time up to the last follow-up in this study, approximately 4 years.</time_frame>
    <description>The percentage of participants who have new HCV infection at any time up to the last follow-up in this study out of participants who achieved SVR in Part 1 or Part 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Percentage of subjects who achieve SVR12 summarized by formulation and age group and across all subjects on the adult formulations.</measure>
    <time_frame>24 weeks after starting study drug depending on treatment duration.</time_frame>
    <description>HCV RNA &lt; LLOQ 12 weeks after the last actual dose of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Percentage of participants who achieve SVR24 by formulation and age group, across all the subjects on the final dose formulations, and across all subjects on the adult formulations.</measure>
    <time_frame>36 weeks after starting study drug depending on treatment duration.</time_frame>
    <description>HCV RNA &lt; LLOQ 24 weeks after the last actual dose of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: Assess the impact of OBV, PTV, RTV with or without DSV and with or without RBV on height</measure>
    <time_frame>Any time up to the last follow-up in this study, approximately 4 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: Assess the impact of OBV, PTV, RTV with or without DSV and with or without RBV on waist circumference</measure>
    <time_frame>Any time up to the last follow-up in this study, approximately 4 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 3: Assess the impact of OBV, PTV, RTV with or without DSV and with or without RBV on tanner staging</measure>
    <time_frame>Any time up to the last follow-up in this study, approximately 4 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Percentage of participants with Alanine aminotransferase (ALT) normalization during treatment</measure>
    <time_frame>During the treatment period (either 12 or 24 weeks)</time_frame>
    <description>ALT less than or equal to upper limit of normal (ULN) at the final treatment visit for participants with ALT greater than ULN at baseline</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Chronic Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>Genotype 4, with or without compensated cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 1a, without cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 1a, with compensated cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 weeks of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype 1b, with or without compensated cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paritaprevir</intervention_name>
    <arm_group_label>Genotype 1b, with or without compensated cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a, without cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a, with compensated cirrhosis</arm_group_label>
    <arm_group_label>Genotype 4, with or without compensated cirrhosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ombitasvir</intervention_name>
    <arm_group_label>Genotype 1b, with or without compensated cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a, without cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a, with compensated cirrhosis</arm_group_label>
    <arm_group_label>Genotype 4, with or without compensated cirrhosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasabuvir</intervention_name>
    <arm_group_label>Genotype 1b, with or without compensated cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a, without cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a, with compensated cirrhosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin</intervention_name>
    <arm_group_label>Genotype 1a, without cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a, with compensated cirrhosis</arm_group_label>
    <arm_group_label>Genotype 4, with or without compensated cirrhosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir</intervention_name>
    <arm_group_label>Genotype 1b, with or without compensated cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a, without cirrhosis</arm_group_label>
    <arm_group_label>Genotype 1a, with compensated cirrhosis</arm_group_label>
    <arm_group_label>Genotype 4, with or without compensated cirrhosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Positive anti-HCV Ab and HCV RNA greater than or equal to 1000 IU/mL at the time of
             screening.

          2. HCV genotype 1 for enrollment into Part 1 and genotype 1 or 4 for enrollment into Part
             2.

          3. Parent or legal guardian with the willingness and ability to provide written informed
             consent and participant willing and able to give assent, as appropriate for age and
             country.

        Exclusion Criteria:

          1. Women who are pregnant, breastfeeding or are considering becoming pregnant

          2. Use of known strong inducers and inhibitors (e.g., gemfibrozil) of cytochrome P450 2C8
             (CYP2C8) in participants receiving dasabuvir, or strong or moderate inducers of CYP3A,
             within 2 weeks or 10 half lives, whichever is longer, of the respective
             medication/supplement prior to study drug administration.

          3. Positive test result for Hepatitis B surface antigen (HbsAg) or anti-HIV antibody (HIV
             Ab) test.

          4. Current enrollment in another interventional clinical study, previous enrollment in
             this study, prior or current use of any investigational or commercially available
             anti-HCV agents other than IFNs or RBV or receipt of any investigational product
             within 6 weeks prior to study drug administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univ California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-2204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Childrens Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Univ Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-5502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Woluwe-Saint-Lambert</city>
        <state>Bruxelles-Capitale</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Wuppertal</name>
      <address>
        <city>Wuppertal</city>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Jorge Children Hospital</name>
      <address>
        <city>San Juan</city>
        <zip>00912-3310</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2015</study_first_submitted>
  <study_first_submitted_qc>June 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C Virus</keyword>
  <keyword>Hepatitis C Genotype 1</keyword>
  <keyword>Hepatitis C Genotype 4</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

